WO2002092606A8 - Fused imidazolidine derivatives, process for preparation of the same and use thereof - Google Patents

Fused imidazolidine derivatives, process for preparation of the same and use thereof

Info

Publication number
WO2002092606A8
WO2002092606A8 PCT/JP2002/004640 JP0204640W WO02092606A8 WO 2002092606 A8 WO2002092606 A8 WO 2002092606A8 JP 0204640 W JP0204640 W JP 0204640W WO 02092606 A8 WO02092606 A8 WO 02092606A8
Authority
WO
WIPO (PCT)
Prior art keywords
same
optionally substituted
fused
preparation
substituted hydrocarbyl
Prior art date
Application number
PCT/JP2002/004640
Other languages
French (fr)
Japanese (ja)
Other versions
WO2002092606A1 (en
Inventor
Yasunori Funabashi
Masayuki Takizawa
Shinji Morimoto
Kohei Notoya
Original Assignee
Takeda Chemical Industries Ltd
Yasunori Funabashi
Masayuki Takizawa
Shinji Morimoto
Kohei Notoya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Yasunori Funabashi, Masayuki Takizawa, Shinji Morimoto, Kohei Notoya filed Critical Takeda Chemical Industries Ltd
Publication of WO2002092606A1 publication Critical patent/WO2002092606A1/en
Publication of WO2002092606A8 publication Critical patent/WO2002092606A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds represented by the general formula (I) and having excellent inhibitory activity against the degradation of cartilage matrix; or salts or sulfoxides of the same: (I) wherein R1 is -(S)n-R2 (wherein R2 is optionally substituted hydrocarbyl or the like; and n is an integer of 0 to 2) or the like; R5 is hydrogen, optionally substituted hydrocarbyl, or the like; symbol (II) is a group represented by the general formula (III) or the like; and symbol (IV) is a group represented by the general formula (V) or the like: (II) (III) (IV) (V) [wherein R6 is hydrogen, optionally substituted hydrocarbyl, or the like; R10 is -ZR15 (wherein Z is -SO2- or the like; and R15 is optionally substituted hydrocarbyl or the like) or the like; and R11 is hydrogen or the like].
PCT/JP2002/004640 2001-05-15 2002-05-14 Fused imidazolidine derivatives, process for preparation of the same and use thereof WO2002092606A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-144608 2001-05-15
JP2001144608 2001-05-15

Publications (2)

Publication Number Publication Date
WO2002092606A1 WO2002092606A1 (en) 2002-11-21
WO2002092606A8 true WO2002092606A8 (en) 2002-12-19

Family

ID=18990527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/004640 WO2002092606A1 (en) 2001-05-15 2002-05-14 Fused imidazolidine derivatives, process for preparation of the same and use thereof

Country Status (1)

Country Link
WO (1) WO2002092606A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069999A2 (en) * 2003-02-04 2004-08-19 Takeda Pharmaceutical Company Limited Screening method
ES2265276B1 (en) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
ES2320961B1 (en) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) PHENOL AS BETA2 ADRENERGIC RECEIVER AGONISTS.
WO2009084653A1 (en) 2007-12-28 2009-07-09 Takeda Pharmaceutical Company Limited Method for screening of cell-protecting agent
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
BR112020006594A2 (en) 2017-10-02 2020-12-15 Arixa Pharmaceuticals, Inc. AZTREONAM DERIVATIVES AND USES OF THE SAME
JP7437847B2 (en) 2018-10-01 2024-02-26 アリクサ ファーマシューティカルズ、インコーポレイテッド Derivatives of relebactam and their uses
CN110156620B (en) * 2019-07-02 2022-04-15 中节能万润股份有限公司 Preparation method of tranexamic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179276A (en) * 1977-02-01 1979-12-18 E. I. Du Pont De Nemours And Company Novel imidazothiazine-1,3 (2H)-diones
GB9212486D0 (en) * 1992-06-12 1992-07-22 Erba Carlo Spa Derivatives of substituted imidazo benzoxazin-1-one and process for their preparation
GB9410469D0 (en) * 1994-05-25 1994-07-13 Erba Farmitalia Imidazolylalkyl derivatives of imidazo (5,1-c) (1,4) benzoxazin-1-one and process for their preparation
AU3106997A (en) * 1996-06-14 1998-01-07 Kaken Pharmaceutical Co., Ltd. Bicyclic hydantoin derivatives, intermediates for the preparation thereof, process for the preparation of them, and herbicides containing the same as active ingredient
AU4135397A (en) * 1996-09-06 1998-03-26 Takeda Chemical Industries Ltd. Condensed 4,5,6,7-tetrahydrobenzo{c}thiophenes as enhancer for cell differentiation induction factor action
WO1998039313A1 (en) * 1998-03-04 1998-09-11 Monsanto Company Thioaryl sulfonamide hydroxamic acid compounds
NZ518369A (en) * 1999-10-20 2003-09-26 Tanabe Seiyaku Co 1,3 or 1,8-Diazabicyclo octane or nonane derivatives or tricyclic derivatives useful as inhibitors of alphaL-beta2 mediated cell adhesion

Also Published As

Publication number Publication date
WO2002092606A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
CA2096969A1 (en) 6-0-methylerythromycin a derivatives
WO2002092606A8 (en) Fused imidazolidine derivatives, process for preparation of the same and use thereof
AU4798000A (en) Triarylimidazoles
AU6576898A (en) Fungicidal trifluorophenyl-triazolopyrimidines
GB0007405D0 (en) Compounds
WO1999030548A3 (en) Method for the preparation of citalopram
HUS1600015I1 (en) Process for preparing 2-alkyl-3-aminothiophene derivatives and new 3-aminothiophene derivatives
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
CA2065799A1 (en) Thiazolidinedione derivatives, their production and their use
CA2070663A1 (en) Sulfonating agent and process
CA2357038A1 (en) Medical compositions comprising 1,4-benzothiazepine derivatives for the treatment of atrial fibrillation
CA2385200A1 (en) 4-hydroxybiphenyl hydrazide derivatives
CA2362217A1 (en) Process for preparing phenylpyrazole pesticidal intermediates
EP1550651A4 (en) Glycerol derivative
AU5390900A (en) Potassium channel blocking agents
UA80839C2 (en) 1-substituted 4-nitroimidazole compound and process for producing the same
HK1054388A1 (en) Process for preparing a substituted imidazopyridine compound.
IL152632A0 (en) Trimethyldecenyl compounds
CA2195975A1 (en) An improved process for preparing side chain derivatives of cyclohexapeptidyl lipopeptides
CA2360677A1 (en) Anticonvulsant derivatives useful in treating bulimia nervosa
EP1118615A4 (en) Novel salts of pyridopyrazine compound and crystals thereof
ZA99440B (en) Condensed aromatic heterocyclic cyclopentenopyridine derivative.
CA2366600A1 (en) A process for the preparation of 1,4,7,10-tetraazacyclododecane
HK1079198A1 (en) Nobel process for the preparation of pyrazolopyrimidiones
EP1346985A4 (en) Pyrimidine derivatives and process for preparing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE IN ENGLISH REPLACED BY CORRECT TITLE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP